Details

Autor(en) / Beteiligte

• Jensen, Anders Kirkegaard
• Chatzidionysiou, Katerina
• Torp, Christopher Kirkegaard
• Sørensen, Anne Sofie
• Tenstad, Helene Broch
• Schäfer, Valentin S.
• Kostine, Marie
• Jacobsen, Søren
• Leipe, Jan
• Kragstrup, Tue Wenzel

Titel

Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy

Ist Teil von

• Biomedicine & pharmacotherapy, 2022-04, Vol.148, p.112687-112687, Article 112687

Ort / Verlag

France: Elsevier Masson SAS

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is a relatively new disease entity caused by ICI agents during cancer therapy. Reactive arthritis (ReA) is a well-known disease entity caused by urogenital or gastrointestinal bacterial infection or pneumonia. In this sense, ICI-IA and ReA are both defined by a reaction to a well-specified causal event. As a result, comparing these diseases may help to determine therapeutic strategies. We compared ICI-IA and ReA with special focus on pharmacological management. Specifically regarding treatment, we conducted a literature search of studies published in the PubMed database. Inclusion criteria were studies on treatment with non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GC), or disease modifying antirheumatic drugs (DMARDs) in ICI-IA or ReA. During systematic selection, 21 studies evaluating ICI-IA and 14 studies evaluating ReA were included. In ICI-IA, prospective and retrospective studies have shown effects of non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoid (GC), sulfasalazine (SSZ), methotrexate (MTX), hydroxychloroquine (HCQ) and TNFi. In ReA, retrospective studies evaluated NSAIDs and GC. A randomized controlled trial reported the effect of SSZ, and a retrospective study reported the effect of MTX and SSZ in combination with tumor necrosis factor alpha inhibition (TNFi). For both entities, small case reports show treatment effects of interleukin 6 receptor inhibition (IL-6Ri). This literature review identified both similarities and differences regarding the pathogenesis and clinical features of ReA and ICI-IA. Studies on treatment reported effectiveness of NSAIDs, GC, MTX, SSZ and TNFi in both diseases. Further, small case reports showed effects of IL-6Ri. [Display omitted] •ICI-IA and ReA are both characterized by a synovial reaction to a well-defined causal event.•There were both similarities and differences in the clinical features of ReA and ICI-IA.•We reveal the efficacy of several csDMARDs and bDMARDs in both ReA and ICI-IA.•The potential for a self-limiting disease course is important for choice of treatment strategy.